Type and pattern of illicit drug use and access to health care services for HIV-infected people

AIDS Patient Care and STDs

Volumn 21, Issue SUPPL. 1, 2007, Pages

  Sohler, Nancy L ^a   Wong, Mitchell D ^c   Cunningham, William E ^c   Cabral, Howard ^b   Drainoni, Mari Lynn ^b   Cunningham, Chinazo O ^d  

^a CITY UNIVERSITY OF NEW YORK MEDICAL SCHOOL   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANALGESIC AGENT; ANTIRETROVIRUS AGENT; CANNABIS; CENTRAL STIMULANT AGENT; COCAINE; DIAMORPHINE; ILLICIT DRUG; OPIATE; SEDATIVE AGENT;

ADULT; AMBULATORY CARE; ARTICLE; COCAINE DEPENDENCE; DISEASE COURSE; DRUG ABUSE PATTERN; EMERGENCY WARD; FEMALE; FOLLOW UP; HEALTH BEHAVIOR; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE UTILIZATION; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; OUTCOME ASSESSMENT; PROGNOSIS; UNITED STATES;

ADULT; AMBULATORY CARE; ANALGESICS, OPIOID; ANTI-HIV AGENTS; COCAINE; COMMUNITY-INSTITUTIONAL RELATIONS; DELIVERY OF HEALTH CARE; FEMALE; HEALTH SERVICES ACCESSIBILITY; HEALTH STATUS; HIV INFECTIONS; HIV-1; HUMANS; MALE; PRIMARY HEALTH CARE; STREET DRUGS; SUBSTANCE-RELATED DISORDERS;

EID: 34250864983     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2007.9985     Document Type: Article

References (41)

1. Glynn M, Rhodes, P. Estimated HIV prevalence in the United States at the end of 2003 [Abstract 595]. National HIV Prevention Conference. Atlanta: 2005.
2. Tucker JS, Burnam MA, Sherbourne CD, Kung FY, Gifford AL. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med 2003;114:573-580.
3. Bassetti S, Battegay M, Furrer H, et al. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 1999;21:114-119.
4. Carrieri MP, Moatti JP, Vlahov D, Obadia Y, Reynaud-Maurupt C, Chesney M. Access to antiretroviral treatment among French HIV infected injection drug users: The influence of continued drug use. MANIF 2000 Study Group. J Epidemiol Community Health 1999;53:4-8.
5. Celentano DD, Vlahov D, Cohn S, Shadle VM, Obasanjo O, Moore RD. Self-reported antiretroviral therapy in injection drug users. JAMA 1998;280:544-546.
6. Chaisson RE, Keruly JC, Moore RD. Race, sex, drug use, and progression of human immunodeficiency virus disease. N Engl J Med 1995;333:751-756.
7. Murri R, Fantoni M, Del Borgo C, et al. Intravenous drug use, relationship with providers, and stage of HIV disease influence the prescription rates of protease inhibitors. J Acquir Immune Defic Syndr 1999;22:461-466.
8. Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States: Results from the HIV Cost and Services Utilization Study. JAMA 1999;281:2305-2315.
9. Hogg RS, Heath KV, Yip B, Craib KJ, O'Shaughnessy MV, Schechter MT, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998;279(6):450-454.
10. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Federation National des Centres de Lutte contre le SIDA. AIDS 1997;11(12):F101-F105.
11. Palella FJ, Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338(13):853-860.
12. Arnsten JH, Demas PA, Grant RW. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med 2002;17(5):377-381.
13. Poundstone KE, Chaisson RE, Moore RD. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS 2001;15(9):1115-1123.
14. Goldstein RB, Rotheram-Borus MJ, Johnson MO, Weinhardt LS, Remien RH, Lightfoot M, et al. Insurance coverage, usual source of care, and receipt of clinically indicated care for comorbid conditions among adults living with human immunodeficiency virus. Med Care 2005;43(4):401-10.
15. Fleishman JA, Gebo KA, Reilly ED, et al. Hospital and outpatient health services utilization among HIV-infected adults in care 2000-2002. Med Care 2005; 43(Suppl):III40-52.
16. Cunningham CO, Sohler NL, Berg KM, Shapiro S, Heller D. Type of substance use and access to HIV-related health care. AIDS Patient Care STDs 2006;20: 399-407.
17. Mor V, Fleishman JA, Dresser M, Piette J. Variation in health service use among HIV-infected patients. Med Care 1992;30:17-29.
18. Cronquist A, Edwards V, Galea S, Latka M, Vlahov D. Health care utilization among young adult injection drug users in Harlem, New York. J Subst Abuse 2001;13(1-2):17-27.
19. Palepu A, Strathdee SA, Hogg RS, Anis AH, Rae S, Cornelisse PG, et al. The social determinants of emergency department and hospital use by injection drug users in Canada. J Urban Health 1999;76(4):409-418.
20. Strathdee SA, Palepu A, Cornelisse PG, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA 1998;280(6):547-549.
21. Berg KM, Demas PA, Howard AA, Schoenbaum EE, Gourevitch MN, Arnsten JH. Gender differences in factors associated with adherence to antiretroviral therapy. J Gen Intern Med 2004;19:1111-1117.
22. Webber MP, Schoenbaum EE, Gourevitch MN, Buono D, Klein RS. A prospective study of HIV disease progression in female and male drug users. AIDS1999; 13:257-262.
23. Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr 2001;27:251-259.
24. Clough LA, D'Agata E, Raffanti S, Haas DW. Factors that predict incomplete virological response to protease inhibitor-based antiretroviral therapy. Clin Infect Dis 1999;29:75-81; discussion 82-84.
25. Rajabiun S, Cabral H, Tobias C, Relf M. Program design and evaluation stategies for the Special Projects of National Significance Outreach Initiative. AIDS Patient Care STDs 2007;21(Suppl 1)S-9-S-19.
26. McLellan AT, Luborsky L, Woody GE, O'Brien CP. An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. J Nerv Ment Dis 1980;168:26-33.
27. Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA 1999;281(24)2305-2315.
28. U.S. Department of Health and Human Services and the Panel on Clinical Practices for the Treatment of HIV Infection. Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents. 2005.
29. Huba GJ, Melchior LA. Module 4A: Services Needed and Received Form. Culver City, CA: The Measurement Group, 1997. www.TheMeasurementGroup. com (Last accessed March 29, 2007).
30. Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: Construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220-233.
31. Ware JE Jr, Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: Summary of results from the Medical Outcomes Study. Med Care 1995;33(4 Suppl):AS264-279.
32. Masson CL, Sorensen JL, Phibbs CS, Okin RL. Predictors of medical service utilization among individuals with co-occurring HIV infection and substance abuse disorders. AIDS Care 2004;16:744-755.
33. Cohen E, Navaline H, Metzger D. High-risk behaviors for HIV: A comparison between crack-abusing and opioid-abusing African-American women. J Psychoactive Drugs 1994;26:233-241.
34. McCoy CB, Metsch LR, Chitwood DD, Miles C. Drug use and barriers to use of health care services. Subst Use Misuse 2001;36:789-806.
35. Smith MY, Rapkin BD, Winkel G, Springer C, Chhabra R, Feldman IS. Housing status and health care service utilization among low-income persons with HIV/AIDS. J Gen Intern Med 2000;15:731-738.
36. Kalichman SC, Graham J, Luke W, Austin J. Perceptions of health care among persons living with HIV/AIDS who are not receiving antiretroviral medications. AIDS Patient Care STDs 2002;16: 233-240.
37. Knowlton A, Arnsten J, Eldred L, et al. Individual, interpersonal, and structural correlates of effective HAART use among urban active injection drug users. J Acquir Immune Defic Syndr 2006;41:486-492.
38. Mizuno Y, Purcell D, Borkowski TM, Knight K. The life priorities of HIV-seropositive injection drug users: Findings from a community-based sample. AIDS Behav 2003;7:395-403.
39. Korthuis PT, Asch S, Mancewicz M, et al. Measuring medication: Do interviews agree with medical record and pharmacy data? Med Care 2002;40:1270-1282.
40. Cunningham CO, Li, Xuan, Sohler NL. A comparison of HIV health services utilization measures in a marginalized population: Self-report versus medical records. Med Care (in press).
41. Ford B.L. An overview of hot-deck procedures. In: WB Madow, I Olkin, DB Rubin (eds.) Incomplete data in sample surveys. New York: Academic Press, 1983, pp 183-207.